Management of adenocarcinoma of prostate with diethylstilbestrol diphosphate and cyclophosphamide.
Eleven patients with terminal metastatic prostatic carcinoma were selected for a pilot study to evaluate how effective diethylstilbestrol diphosphate (Stilphostrol) and cylcophosphamide (Cytoxan) are in this disease.  Six of 7 patients had a good response when treated with diethylstilbestrol diphosphate.  The mean duration of response was 6.4 months.  All 6 patients given cyclophosphamide had marked relief of pain and increased mobility.  Of these, 3 died twelve, sixteen, and nineteen weeks, respectively, following initiation of therapy while still benefiting from pain relief.  The mean duration of response was 14.8 weeks.
D000230:Adenocarcinoma / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004054:Diethylstilbestrol / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010166:Palliative Care; D010865:Pilot Projects; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D004054:Diethylstilbestrol; D003520:Cyclophosphamide